



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	Ms_BJMMR_20784
Title of the Manuscript:	A pilot, randomized sham control trial of autologous bone marrow stem cells in acute ischemic central retinal vein occlusion (sic study)
Type of the Article	Original research paper

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<p>Thanks for the author's efforts , the revised manuscript had shown very good improvement through considering the reviewer's comments but still there are some points that are misunderstood and other points need some revision Theses points although few but very important to be revised before considering this article for publication</p> <ol style="list-style-type: none"> 1- Modifying " bone marrow stem cells " to "bone marrow derived mononuclear CD34+ cells " after your revision is inappropriate. You should modify it to "bone marrow derived mononuclear cells " since you worked with the whole cell layer (i.e. all mononuclear cells and not with the CD34+ cell population only , which is a population of hematopietic stem cells included in the mononuclear cell layer) Accordingly, delete "CD 34+" from <ol style="list-style-type: none"> a- Title b- Page 1 line 7 c- Page 2 line 35 in key words d- Page 5 line 100 (CD 34+ count) e- Page 8 line 187 2- Page 4 line 70, "stem cells" should be changed to "mononuclear cell layer". Lines 71,72 delete " and the final product..... till the end of the sentence" 3- Page 5 lines 106,107,108 should come after line 100 4- Flow cytometric characterization of MNC should be for stem cells populations present in MNC layer . As I can see you selected CD34 and CD45 as hematopietic cell markers , but why did you characterized the T lymphocytes (not your target cell) with CD 3,CD 4 and CD 8 ???, why do you want to prove their presence ??? You should instead have chosen one or two mesenchymal stem cells markers ex CD29, CD 44, CD 109 ...etc to prove the presence of different stem cells population in the isolated MNC layer. Please verify characterizing T lymphocytes in your study or otherwise don't mention T lymphocytes markers in your manuscript 5- Page 5 line 113, (containing 6-8 million stem cells) should be (6-8 million MNCs) , also you should mention in which solution these cells were suspended (media, buffer ...etc) 6- Page 5 line 114, " the combination " is better referred to as "the mixture" 7- Page 6 line 125 , 12 months follow up is mentioned in the methodology but again no full data available at 12 month in the supplements you added, please modify accordingly. 8- You mentioned that you added a figure for case 2 but unfortunately you didn't , I can't see it in the revised manuscript. 	



SDI FINAL EVALUATION FORM 1.1

9- Page 3 line 49 ,NVI is an abbreviation not mentioned before 10- Page 1 line 6 , please add a coma after (CRVO)	
--	--

Reviewer Details:

Name:	Radwa A Mehanna
Department, University & Country	Medical Physiology Department, Alexandria University, Egypt